Prostate Cancer Foundation and Bayer Announce: 2023 Bayer-PCF Darolutamide Challenge Awards For Clinical Investigations on Novel Uses of Darolutamide in Prostate Cancer REQUEST FOR APPLICATIONS

Reno, Nevada (UroToday.com) -- The Prostate Cancer Foundation (PCF) and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards for novel investigator-initiated clinical investigations with correlative research for darolutamide in prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF and Bayer seek high-risk, currently unfunded projects from academic institutions in the United States (U.S. only).

Bayer-PCF Challenge Awards:

  • Composed of a team of at least three (3) investigators from non-profit academic research centers in the U.S., including one young investigator (see PCF Challenge Award Team requirements below).
  • Support novel clinical investigations with correlative research for darolutamide in prostate cancer, over a duration of two years.
  • Provide up to a total of $1 million per Approximately $3 million will be designated for this award mechanism.
  • Cover only direct research costs and travel to the Annual PCF Scientific Retreat.
  • IRB submission and preferably approval is desired at time of application.

Research Proposals:

  • This RFP seeks proposals for novel investigator-initiated clinical investigations with correlative research for darolutamide in prostate cancer. A novel clinical trial must be part of the proposed research project.
  • Investigations may be in the following topic areas:
  • Novel clinical spaces for darolutamide in prostate cancer.
  • New combination treatment approaches with established or experimental drugs that capitalize on different mechanisms of action for eradication of prostate cancer.
  • Studies must include correlative research that aims to help better define biomarkers or other understandings that will improve the clinical use of darolutamide in patients with prostate cancer, to increase efficacy and/or quality of life.
  • All studies should include comprehensive statistical plans for clinical trial enrollment and power calculations.
  • All studies must include plans for enrolling diverse participant populations with appropriate representation of ethnic and racial minority groups.
  • Applications for trials testing combinations with non-Bayer assets may seek clinical trial support from other companies or organizations.

The Bayer-PCF Challenge Award Team:

  • Should be composed of at least 3 investigators capable of providing unique scientific expertise to the solution of this significant problem in prostate cancer research.
  • May be assembled from one institution, or several institutions, located in the U.S.
  • Must embed at least one young investigator as an integral contributor to the team. The young investigator may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six- years following completion of a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equivalent) or subsequent mentored academic or clinical training program. He or she should not have been granted commitments for more than $300,000 in direct research funding from all sources including institutional funds at the time of this application.
  • Applicants who are under-represented in biomedical research are highly encouraged to apply.
Source: Prostate Cancer Foundation (PCF). (2023). Prostate Cancer Foundation and Bayer Announce: 2023 Bayer-PCF Darolutamide Challenge Awards For Clinical Investigations on Novel Uses of Darolutamide in Prostate Cancer REQUEST FOR APPLICATIONS [Press release]. https://www.pcf.org/news/.